Skip to main content

Merck & Co. (MRK) Stock Price & Market Analysis

MRK · NYSE · Pharmaceuticals

Regular sessionRegular-session print

$143.37

▼ -$1.09(-0.75%)4:02 PM ET - vs previous close

Quote as of Nov 17, 2026, 4:02 PM EST

Regular-session close · Nov 17, 2026, 4:02 PM EST.

Last session41%
$142.31L Nov 17 '26$144.89H Nov 17 '26
52-week range79%
$92.11$156.92
Long-term rangesAvailable history
Available history(2000-11-17)91%
$10.55L Mar 9 '09$156.00H Aug 25 '26

Historical range: 2000-11-17–2026-11-17. Earlier trading may not be included.

Loading price chart…

Data dates

PriceDelayedLast traded

FundamentalsLast checked

AnalystLast checked

NewsLatest item

What matters next

Next important events

  1. Feb 2, 2027Next earnings (est.) · After market closeEstimated · After market close · Last verified 2026-11-17

Countdown

77 days out

Reported fundamentals

MRK financial overview

Annual revenue

USD 65.01B

Sales for the fiscal year ended Dec 31, 2025. This is not trailing twelve-month revenue.

Revenue change

+1.3%

Change versus the fiscal year ended Dec 31, 2024.

Net profit margin

28.1%

Net income divided by revenue for the fiscal year ended Dec 31, 2025. This is not the trailing margin.

These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.

Company · ProfileAbout Merck & Co. (MRK)Sector, leadership, and how Merck & Co. earns its revenue.

Merck & Co.

NYSE · MRK · US

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Company overview as of Nov 17, 2026.

Sector
Healthcare
Industry
Pharmaceuticals
Headquarters
Rahway, NJ, United States
Country
US
Founded
1891
Employees
73,000
CEO
Mr. Robert M. Davis J.D.
Exchange
NYSE
Business model & operating resultsExplore business exposure, reported operating measures and the figures behind growth and profitability claims.

Company website ↗

Narrative versus numbers

Demand is expanding

Supporting observation: 4.7%

Year-over-year growth in the latest quarter. This differs from the fiscal-year revenue change shown above. · Source timestamp: Sep 30, 2026

Growth produces accounting profit

Supporting observation: 3.6%

Net margin; the source did not supply a reporting period. Do not compare this reading with the quarterly or fiscal-year figures above. A positive margin does not establish cash generation. · Source timestamp: Nov 17, 2026, 3:13 PM EST

The business generates cash after investment

Supporting observation: USD 5.52B

Latest free cash flow from the statement feed. It is not a forecast and may cover a different period from the fiscal-year figures above. · Source timestamp: Sep 30, 2026

These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.

Operating measures

Revenue
$18.09Bquarter ended Sep 30, 2026
EPS
$2.04quarter ended Sep 30, 2026
Capital expenditure
$1.04Bquarter ended Sep 30, 2026
Free cash flow
$5.52Bquarter ended Sep 30, 2026
Free cash flow margin
30.5%quarter ended Sep 30, 2026
Operating cash / net income
1.29×quarter ended Sep 30, 2026
Revenue growth year over year
4.7%quarter ended Sep 30, 2026
Competitors & comparisonsCompare industry peers, reporting periods and related funds. Business mix and valuation bases may differ.
Valuation & fund comparisonsExplore dated peer valuations, growth comparisons and related funds.

Governance & sustainability

Find proxy statements and annual reports

Data sources: Finnhub · SEC Companyfacts · Yahoo Finance

Market data is for information only and is not trading advice. Prices and fundamentals may be delayed, reflect an earlier observation, be incomplete, or be revised. Read the data methodology or the full disclaimer.
Research tools
After hours

Regular hours: 9:30 AM–4:00 PM America/New_York

Next open: 2026-11-18 · 9:30 AM America/New_York

Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.